Periodontal repair in dogs: recombinant human bone morphogenetic protein-2 significantly enhances periodontal regeneration.
This study evaluated bone and cementum regeneration following periodontal reconstructive surgery using recombinant human bone morphogenetic protein-2 (rhBMP-2) in six beagle dogs. Surgically created mandibular supraalveolar premolar tooth defects in contralateral jaw quadrants were randomly assigned to receive rhBMP-2 or control vehicle. Clinical defect height was prepared to 5 mm. rhBMP-2 was applied with synthetic bioerodable particles and autologous blood using 20 micrograms rhBMP-2 per 100 microliters implant volume. Flaps were advanced to submerge the teeth and sutured. The dogs were sacrificed 8 weeks postsurgery. Histometric recordings included defect height, height and area of alveolar bone regeneration, height of cementum regeneration, root resorption, and ankylosis. Group means, standard deviations, and P values are shown (Student t test; n = 6). Histometric defect height for rhBMP-2 and control defects was 3.7 +/- 0.3 and 3.9 +/- 0.4 mm, respectively (P = 0.446). Height of alveolar bone regeneration amounted to 3.5 +/- 0.6 and 0.8 +/- 0.6 mm for rhBMP-2 and control defects, respectively (P = 0.000). Corresponding values for bone area were 8.4 +/- 4.5 and 0.4 +/- 0.5 mm2, respectively (P = 0.006). Cementum regeneration was observed in all experimental defects (17/17) and in 15 out of 17 controls, averaging 1.6 +/- 0.6 and 0.4 +/- 0.3 mm for rhBMP-2 and control defects, respectively (P = 0.005). Small amounts of root resorption were seen in rhBMP-2 defects, whereas controls exhibited substantial resorption (0.2 +/- 0.1 and 1.1 +/- 0.3 mm, respectively; P = 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
Sigurdsson
T J
TJ
Loma Linda University, CA, USA.
Lee
M B
MB
Kubota
K
K
Turek
T J
TJ
Wozney
J M
JM
Wikesjö
U M
UM
D016301:Alveolar Bone Loss / Q000188:drug therapy* / Q000601:surgery; D000818:Animals; D000844:Ankylosis; D019485:Bone Morphogenetic Proteins; D001861:Bone Regeneration / Q000187:drug effects*; D003739:Dental Cementum / Q000187:drug effects* / Q000502:physiology; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D006133:Growth Substances / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019344:Lactic Acid; D008297:Male; D011100:Polyglycolic Acid; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000494:pharmacology / Q000627:therapeutic use; D011506:Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D011897:Random Allocation; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012038:Regeneration / Q000187:drug effects*; D012391:Root Resorption
D019485:Bone Morphogenetic Proteins; D006133:Growth Substances; D011108:Polymers; D011506:Proteins; D011994:Recombinant Proteins; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid